Action SHJB.F SHANGHAI JUNSHI BIOSCIENCES CO., LTD.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Shanghai Junshi Biosciences Co., Ltd. OTC Markets

Actions

SHJB.F

CNE100003FF7

Marché Fermé - OTC Markets
Autres places de cotation
 14:51:46 20/03/2024 		Varia. 5j. Varia. 1 janv.
1,86 USD -9,71 % Graphique intraday de Shanghai Junshi Biosciences Co., Ltd. -.--% -13,49 %
13/06 Un médicament anticancéreux de Junshi Biosciences obtient un certificat d'enregistrement de l'organisme de réglementation chinois MT
12/06 Shanghai Junshi Biosciences Co. reçoit le certificat d'enregistrement des médicaments délivré par l'administration nationale des produits médicaux CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Junshi Biosciences' Cancer Drug Gets Registration Certificate from Chinese Regulator
Shanghai Junshi Biosciences Co., Ltd. Receives Drug Registration Certificate Issued by the National Medical Products Administration
Junshi Bio Achieves Primary Endpoints in Phase 3 Trial of Liver Cancer Treatment
Shanghai Junshi Biosciences Cancer Drug Shows Positive Phase III Trial Results
Junshi Biosciences Announces Phase 3 Study of Toripalimab Combined with Bevacizumab for the First-line Treatment of Advanced Hepatocellular Carcinoma Meets Primary Endpoint
Shanghai Junshi Biosciences Co., Ltd. Announces Phase III Clinical Study of Toripalimab in Combination with Bevacizumab for the First-Line Treatment of Advanced Hepatocellular Carcinoma
Shanghai Junshi Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
Shanghai Junshi Biosciences Receives Hong Kong Approval for Cancer Drug Toripalimab
Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
Shanghai Junshi Biosciences Co., Ltd. Receives Notice from the Drug Office, Department of Health, the Government of the Hong Kong Special Administration Region
Shanghai Junshi Biosciences Co., Ltd. Announces Executive Changes
Junshi Biosciences Gets Nod to Register Toripalimab Injection
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer
Shanghai Junshi Biosciences Co., Ltd. Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer
Shanghai Junshi Biosciences Supplemental NDA for Lipid Drug Accepted by NMPA
Shanghai Junshi Biosciences Co., Ltd. Announces the Acceptance of the Supplemental New Drug Applications for Ongericimab Injection
Tranche Update on Shanghai Junshi Biosciences Co., Ltd.'s Equity Buyback Plan announced on September 10, 2023.
Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates
Shanghai Junshi Biosciences' Loss Narrows in 2023, Misses Estimates
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action 1877
  4. Action SHJB.F
  5. Actualités Shanghai Junshi Biosciences Co., Ltd.
  6. Autres langues